WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-06-02·Latest →

Medtronic (MDT) Stock Analysis

UW

MDT Equity Research — UNDERWEIGHT — June 2026

← LLYMRK →

Rating date

Jun 2, 2026

69 days ago

Desk view

UW

5D move

+9.41%

Incorrect (early)

Peer rank

9p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · MDT

Here is the equity analysis for MDT (Medtronic plc) as of June 2, 2026.

Desk rating

UW

Tactical UW · 12M OW

Horizon

Tactical UNDERWEIGHT · 12M OVERWEIGHT

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

UNDERWEIGHT

Catalysts

  • Bear market entrenched: MDT is in a clear downtrend with price below both the 50-day and 200-day SMAs (death cross configuration). The 50-day SMA is declining rapidly.
  • RSI near oversold but not confirmed: At 31.2, the RSI is close to the 30 oversold threshold but hasn't crossed it. The prior May 11 reading of 23.0 shows conditions can stay extreme.
  • Failed MACD crossover is a warning: The brief bullish MACD crossover on May 29 has already reversed, suggesting the attempted bounce lacked conviction.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

MDT Research Note

Full desk note for Jun 2, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

32 min read

WebserviceX · Agentic Research Desk

MDT Equity Research Note

Published Jun 2, 2026 · Desk view UNDERWEIGHT · Generated 2026-06-03T05:25:24Z · Maintained by Walter Vijayakumar · Methodology · Track record

MDT Stock Rating Summary

MDT bias

UNDERWEIGHT

Horizon

Tactical UNDERWEIGHT · 12M OVERWEIGHT

MDT key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

MDT catalyst watch

Bear market entrenched: MDT is in a clear downtrend with price below both the 50-day and 200-day SMAs (death cross configuration). The 50-day SMA is declining rapidly.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

+9.41%Incorrect (early)Peer 9p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-09T07:21:42.845688+00:00.

5D move

+9.41%

2026-06-02 → 2026-06-08

Outcome

Incorrect (early)

5D trend

-4.96%

Vol (20D ann.)

+22.02%

vs SPY: -6.16%

Close 73.75 → — (USD, vendor closes)

Batch scorecard · 2026-06-02 · MDT

Publish QC

passed
Expand

Pipeline fingerprint 781c0b04aa680fac

No QC issues recorded.